Gadicke Ansbert's Form 4 filing
TCR2 Therapeutics Inc. (TCRR) · filed May 24, 2023
- Accession no.
- 0001209191-23-031888
- Filed
- May 24, 2023
- Trade date
- May 22, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 2 derivative transactions. Open-market sales total $131.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gadicke AnsbertCIK 0001134655 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 22, 2023 | Common Stock | XIn-the-money exerciseAcquired | +178,269 | $0.74 | +$131,919.06 | 374,171 | Indirect | |
| May 22, 2023 | Common Stock | SSaleDisposed | −70,170 | $1.88 | −$131,919.6 | 304,001 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 22, 2023 | Common Stock | XIn-the-money exerciseDisposed | −42,761 | $0.00 | $0 | 0 | Indirect | |
| May 22, 2023 | Common Stock | XIn-the-money exerciseDisposed | −135,508 | $0.00 | $0 | 0 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.